Patents by Inventor Michele Pagano
Michele Pagano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11583525Abstract: A method is disclosed for treating a cancer in a subject that involves administering to the subject a therapeutically affective amount of a geranylgeranyltransferase I (GGTase I) inhibitor, such as GGTI-2418, wherein the cancer comprises a defective PTEN, a hyperactivated FBXL2, or a low level of IP3R3. In some embodiments, the method further involves administering to the subject a therapeutically affective amount of an Akt inhibitor.Type: GrantFiled: June 6, 2018Date of Patent: February 21, 2023Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., NEW YORK UNIVERSITYInventors: Said M. Sebti, Michele Pagano, Shafi Kuchay
-
Publication number: 20220143183Abstract: Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more photoswitchable group(s), optionally, one or more linker(s), and one or more ligand(s) for a target protein. PHOTACs may be suitable for use in methods to treat diseases, such as, for example, cancer. PHOTACs may also be suitable for use in methods to induce selective degradation of a target protein.Type: ApplicationFiled: February 24, 2020Publication date: May 12, 2022Inventors: Dirk TRAUNER, Martin REYNDERS, Bryan MATSUURA, Marleen BEROUTI, Michele PAGANO
-
Publication number: 20210093632Abstract: A method is disclosed for treating a cancer in a subject that involves administering to the subject a therapeutically affective amount of a geranylgeranyltransferase I (GGTase I) inhibitor, such as GGTI-2418, wherein the cancer comprises a defective PTEN, a hyperactivated FBXL2, or a low level of IP3R3. In some embodiments, the method further involves administering to the subject a therapeutically affective amount of an Akt inhibitor.Type: ApplicationFiled: June 6, 2018Publication date: April 1, 2021Inventors: Said M. Sebti, Michele Pagano, Shafi Kuchay
-
Patent number: 9261497Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: GrantFiled: October 16, 2013Date of Patent: February 16, 2016Assignee: New York UniversityInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Publication number: 20150044228Abstract: The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits.Type: ApplicationFiled: February 14, 2014Publication date: February 12, 2015Applicant: NEW YORK UNIVERSITYInventors: Michele Pagano, Frank Mercurio, Weilin Xie, Antonia Lopez-Girona, Angelo Peschiaroli
-
Patent number: 8778905Abstract: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.Type: GrantFiled: November 5, 2012Date of Patent: July 15, 2014Assignee: New York UniversityInventors: Michele Pagano, Jeffrey R. Skaar, Angelo Peschiaroli, N. Valerio Dorrello
-
Patent number: 8753830Abstract: Cdc25A is herein identified as a substrate for ?-TrCP1- or ?-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with ?-TrCP expression or function, or increasing ?-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying ?-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.Type: GrantFiled: May 3, 2013Date of Patent: June 17, 2014Assignee: New York UniversityInventors: Michele Pagano, Luca Busino
-
Publication number: 20140142120Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer in a subject. Also disclosed are methods of inhibiting SCF-Skp2 activity and a method of identifying inhibitors of SCF-Skp2 activity.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: NEW YORK UNIVERSITYInventors: Timothy Cardozo, Michele Pagano, Lily Wu, Leslie I. Gold
-
Patent number: 8586297Abstract: The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.Type: GrantFiled: June 6, 2012Date of Patent: November 19, 2013Assignee: New York UniversityInventors: Michele Pagano, Florian Bassermann
-
Patent number: 8551969Abstract: Cdc25A is herein identified as a substrate for ?-TrCP1- or ?-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with ?-TrCP expression or function, or increasing ?-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying ?-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.Type: GrantFiled: October 14, 2008Date of Patent: October 8, 2013Assignee: New York UniversityInventors: Michele Pagano, Luca Busino
-
Publication number: 20130230862Abstract: Cdc25A is herein identified as a substrate for ?-TrCP1- or ?-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with ?-TrCP expression or function, or increasing ?-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying ?-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.Type: ApplicationFiled: May 3, 2013Publication date: September 5, 2013Applicant: NEW YORK UNIVERSITYInventors: Michele Pagano, Luca Busino
-
Patent number: 8318437Abstract: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.Type: GrantFiled: September 28, 2011Date of Patent: November 27, 2012Assignee: New York UniversityInventors: Michele Pagano, Jeffrey R. Skaar, Angelo Peschiaroli, N. Valerio Dorrello
-
Publication number: 20120277287Abstract: The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.Type: ApplicationFiled: June 6, 2012Publication date: November 1, 2012Applicant: NEW YORK UNIVERSITYInventors: Michele Pagano, Florian Bassermann
-
Patent number: 8216835Abstract: The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.Type: GrantFiled: July 8, 2009Date of Patent: July 10, 2012Assignee: New York UniversityInventors: Michele Pagano, Florian Bassermann
-
Publication number: 20120164656Abstract: The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases, and transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders.Type: ApplicationFiled: December 12, 2011Publication date: June 28, 2012Inventors: Michele Pagano, Frank Mercurio, Weilin Xie, Antonia Lopez-Girona, Angelo Peschiaroli
-
Publication number: 20120157507Abstract: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.Type: ApplicationFiled: September 28, 2011Publication date: June 21, 2012Applicant: NEW YORK UNIVERSITYInventors: Michele Pagano, Jeffrey R. Skaar, Angelo Peschiaroli, N. Valerio Dorrello
-
Patent number: 8119421Abstract: The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits.Type: GrantFiled: December 5, 2008Date of Patent: February 21, 2012Assignee: New York UniversityInventors: Michele Pagano, Frank Mercurio, Weilin Xie, Antonia Lopez-Girona, Angelo Peschiaroli
-
Patent number: 8093043Abstract: The invention relates to modulating BimEL levels (Bcl-2-Interacting Mediator of cell death, Extra Long isoform) to sensitize cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to increasing BimEL levels. In certain embodiments, the invention relates to inhibitors of at least one of ?-TrCP1/2 or RSK1/2 proteins that sensitize tumor cells to chemotherapy-induced death or apoptosis. Additionally, the invention relates to cancer therapies, diagnostics, and methods for identifying novel drugs or drug candidates for increasing BimEL levels.Type: GrantFiled: June 4, 2009Date of Patent: January 10, 2012Assignee: New York UniversityInventors: Michele Pagano, Elinor Dehan
-
Patent number: 8076309Abstract: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.Type: GrantFiled: April 28, 2009Date of Patent: December 13, 2011Assignee: New York UniversityInventors: Michele Pagano, Jeffrey R. Skaar, Angelo Peschiaroli, N. Valerio Dorrello
-
Publication number: 20100212033Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention.Type: ApplicationFiled: December 22, 2008Publication date: August 19, 2010Inventors: Dah Shiam Chiaur, Michele Pagano, Esther Latres